The tumorigenicity of diploid and aneuploid human pluripotent stem cells

Barak Blum; Nissim Benvenisty

doi:10.4161/cc.8.23.10067

The tumorigenicity of diploid and aneuploid human pluripotent stem cells

Barak Blum^*, Nissim Benvenisty

^*Corresponding author for this work

Department of Genetics

Research output: Contribution to journal › Review article › peer-review

117 Scopus citations

Abstract

Human embryonic stem cells (HESCs) and induced pluripotent stem cells (HiPSCs) offer an immense potential as a source of cells for regenerative medicine. However, the ability of undifferentiated HESCs and HiPSCs to produce tumors in vivo presents a major obstacle for the translation of this potential into clinical reality. Therefore, characterizing the nature of HESC- and HiPSC-derived tumors, especially their malignant potential, is extremely important in order to evaluate the risk involved in their clinical use. Here we review recent observations on the tumorigenicity of human pluripotent stem cells. We argue that diploid, early passage, HESCs produce benign teratomas without undergoing genetic modifications. Conversely, HESCs that acquired genetic or epigenetic changes upon adaptation to in vitro culture can produce malignant teratocarcinomas. We discuss the molecular mechanisms of HESC tumorigenicity and suggest approaches to prevent tumor formation from these cells. We also discuss the differences in the tumorigenicity between mouse embryonic stem cells (MESCs) and HESCs, and suggest methodologies that may help to identify cellular markers for culture adapted HESCs.

Original language	English
Pages (from-to)	3822-3830
Number of pages	9
Journal	Cell Cycle
Volume	8
Issue number	23
DOIs	https://doi.org/10.4161/cc.8.23.10067
State	Published - 1 Dec 2009

Bibliographical note

Funding Information:
We are grateful to all the members of the Benvenisty lab for their support, especially Tamar Golan-Lev for providing the karyotype of the cells, and Yoav Mayshar for countless discussions and suggestion. We thank Justin Annes for his help with the writing of the manuscript. B.B. also acknowledges Ittai Ben-Porath for unknowingly provoking ideas. This work was partially supported by funds from the European Community (ESTOOLS, Grant number 018739) and the Herbert Cohn Chair in Cancer Research. We gratefully acknowledge support for this project provided by a grant from Legacy Heritage Fund of New York.

Keywords

Culture adaptation
Human embryonic stem cells
Induced pluripotent stem cells
Teratocarcinoma
Teratoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/cc.8.23.10067

Cite this

@article{0529603c6a624065af752bd5f2b164f7,

title = "The tumorigenicity of diploid and aneuploid human pluripotent stem cells",

abstract = "Human embryonic stem cells (HESCs) and induced pluripotent stem cells (HiPSCs) offer an immense potential as a source of cells for regenerative medicine. However, the ability of undifferentiated HESCs and HiPSCs to produce tumors in vivo presents a major obstacle for the translation of this potential into clinical reality. Therefore, characterizing the nature of HESC- and HiPSC-derived tumors, especially their malignant potential, is extremely important in order to evaluate the risk involved in their clinical use. Here we review recent observations on the tumorigenicity of human pluripotent stem cells. We argue that diploid, early passage, HESCs produce benign teratomas without undergoing genetic modifications. Conversely, HESCs that acquired genetic or epigenetic changes upon adaptation to in vitro culture can produce malignant teratocarcinomas. We discuss the molecular mechanisms of HESC tumorigenicity and suggest approaches to prevent tumor formation from these cells. We also discuss the differences in the tumorigenicity between mouse embryonic stem cells (MESCs) and HESCs, and suggest methodologies that may help to identify cellular markers for culture adapted HESCs.",

keywords = "Culture adaptation, Human embryonic stem cells, Induced pluripotent stem cells, Teratocarcinoma, Teratoma",

author = "Barak Blum and Nissim Benvenisty",

note = "Funding Information: We are grateful to all the members of the Benvenisty lab for their support, especially Tamar Golan-Lev for providing the karyotype of the cells, and Yoav Mayshar for countless discussions and suggestion. We thank Justin Annes for his help with the writing of the manuscript. B.B. also acknowledges Ittai Ben-Porath for unknowingly provoking ideas. This work was partially supported by funds from the European Community (ESTOOLS, Grant number 018739) and the Herbert Cohn Chair in Cancer Research. We gratefully acknowledge support for this project provided by a grant from Legacy Heritage Fund of New York.",

year = "2009",

month = dec,

day = "1",

doi = "10.4161/cc.8.23.10067",

language = "אנגלית",

volume = "8",

pages = "3822--3830",

journal = "Cell Cycle",

issn = "1538-4101",

publisher = "Taylor and Francis Ltd.",

number = "23",

}

TY - JOUR

T1 - The tumorigenicity of diploid and aneuploid human pluripotent stem cells

AU - Blum, Barak

AU - Benvenisty, Nissim

N1 - Funding Information: We are grateful to all the members of the Benvenisty lab for their support, especially Tamar Golan-Lev for providing the karyotype of the cells, and Yoav Mayshar for countless discussions and suggestion. We thank Justin Annes for his help with the writing of the manuscript. B.B. also acknowledges Ittai Ben-Porath for unknowingly provoking ideas. This work was partially supported by funds from the European Community (ESTOOLS, Grant number 018739) and the Herbert Cohn Chair in Cancer Research. We gratefully acknowledge support for this project provided by a grant from Legacy Heritage Fund of New York.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Human embryonic stem cells (HESCs) and induced pluripotent stem cells (HiPSCs) offer an immense potential as a source of cells for regenerative medicine. However, the ability of undifferentiated HESCs and HiPSCs to produce tumors in vivo presents a major obstacle for the translation of this potential into clinical reality. Therefore, characterizing the nature of HESC- and HiPSC-derived tumors, especially their malignant potential, is extremely important in order to evaluate the risk involved in their clinical use. Here we review recent observations on the tumorigenicity of human pluripotent stem cells. We argue that diploid, early passage, HESCs produce benign teratomas without undergoing genetic modifications. Conversely, HESCs that acquired genetic or epigenetic changes upon adaptation to in vitro culture can produce malignant teratocarcinomas. We discuss the molecular mechanisms of HESC tumorigenicity and suggest approaches to prevent tumor formation from these cells. We also discuss the differences in the tumorigenicity between mouse embryonic stem cells (MESCs) and HESCs, and suggest methodologies that may help to identify cellular markers for culture adapted HESCs.

AB - Human embryonic stem cells (HESCs) and induced pluripotent stem cells (HiPSCs) offer an immense potential as a source of cells for regenerative medicine. However, the ability of undifferentiated HESCs and HiPSCs to produce tumors in vivo presents a major obstacle for the translation of this potential into clinical reality. Therefore, characterizing the nature of HESC- and HiPSC-derived tumors, especially their malignant potential, is extremely important in order to evaluate the risk involved in their clinical use. Here we review recent observations on the tumorigenicity of human pluripotent stem cells. We argue that diploid, early passage, HESCs produce benign teratomas without undergoing genetic modifications. Conversely, HESCs that acquired genetic or epigenetic changes upon adaptation to in vitro culture can produce malignant teratocarcinomas. We discuss the molecular mechanisms of HESC tumorigenicity and suggest approaches to prevent tumor formation from these cells. We also discuss the differences in the tumorigenicity between mouse embryonic stem cells (MESCs) and HESCs, and suggest methodologies that may help to identify cellular markers for culture adapted HESCs.

KW - Culture adaptation

KW - Human embryonic stem cells

KW - Induced pluripotent stem cells

KW - Teratocarcinoma

KW - Teratoma

UR - http://www.scopus.com/inward/record.url?scp=74849135201&partnerID=8YFLogxK

U2 - 10.4161/cc.8.23.10067

DO - 10.4161/cc.8.23.10067

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:74849135201

SN - 1538-4101

VL - 8

SP - 3822

EP - 3830

JO - Cell Cycle

JF - Cell Cycle

IS - 23

ER -

The tumorigenicity of diploid and aneuploid human pluripotent stem cells

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this